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Abstract ‘Mapping’ onto generic preference-based out-
come measures is increasingly being used as a means of
generating health utilities for use within health economic
evaluations. Despite the publication of technical guides for
the conduct of mapping research, guidance for the report-
ing of mapping studies is currently lacking. The MAPS
(MApping onto Preference-based measures reporting
Standards) statement is a new checklist, which aims to
promote complete and transparent reporting of mapping
studies. The primary audiences for the MAPS statement are
researchers reporting mapping studies, the funders of the
research, and peer reviewers and editors involved in
assessing mapping studies for publication. A de novo list of
29 candidate reporting items and accompanying explana-
tions was created by a working group comprising six health
economists and one Delphi methodologist. Following a
two-round modified Delphi survey with representatives
from academia, consultancy, health technology assessment
agencies and the biomedical journal editorial community, a
final set of 23 items deemed essential for transparent
reporting, and accompanying explanations, was developed.
The items are contained in a user-friendly 23-item check-
list. They are presented numerically and categorised within
six sections, namely: (1) title and abstract; (2) introduction;
(3) methods; (4) results; (5) discussion; and (6) other. The
MAPS statement is best applied in conjunction with the
accompanying MAPS explanation and elaboration docu-
ment. It is anticipated that the MAPS statement will
improve the clarity, transparency and completeness of
reporting of mapping studies. To facilitate dissemination
and uptake, the MAPS statement is being co-published by
seven health economics and quality-of-life journals, and
broader endorsement is encouraged. The MAPS working
group plans to assess the need for an update of the
reporting checklist in 5 years’ time.
Key Points
This paper summarises the development of the
MAPS reporting statement, a checklist of essential
items that authors should consider when reporting
mapping studies.
It is anticipated that the MAPS reporting statement
will promote clarity, transparency and completeness
of reporting of mapping studies.
1 Introduction
The process of ‘mapping’ onto generic preference-based
outcome measures is increasingly being used as a means of
generating health utilities for application within health
economic evaluations [1]. Mapping involves the
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development and use of an algorithm (or algorithms) to
predict the primary outputs of generic preference-based
outcome measures, i.e. health utility values, using data on
other indicators or measures of health. The source predic-
tive measure may be a non-preference based indicator or
measure of health outcome or, more exceptionally, a
preference-based outcome measure that is not preferred by
the local health technology assessment agency. The algo-
rithm(s) can subsequently be applied to data from clinical
trials, observational studies or economic models containing
the source predictive measure(s) to predict health utility
values in contexts where the target generic preference-
based measure is absent. The predicted health utility values
can then be analysed using standard methods for individ-
ual-level data (e.g. within a trial-based economic evalua-
tion), or summarised for each health state within a
decision-analytic model.
Over recent years there has been a rapid increase in the
publication of studies that use mapping techniques to pre-
dict health utility values, and databases of published studies
in this field are beginning to emerge [2]. Some authors [3]
and agencies [4] concerned with technology appraisals
have issued technical guides for the conduct of mapping
research. However, guidance for the reporting of mapping
studies is currently lacking. In keeping with health-related
research more broadly [5], mapping studies should be
reported fully and transparently to allow readers to assess
the relative merits of the investigation [6]. Moreover, there
may be significant opportunity costs associated with reg-
ulatory and reimbursement decisions for new technologies
informed by misleading findings from mapping studies.
This has led to the development of the MAPS (MApping
onto Preference-based measures reporting Standards)
statement, which we summarise in this paper.
The aim of the MAPS statement is to provide recom-
mendations, in the form of a checklist of essential items,
which authors should consider when reporting a mapping
study. It is anticipated that the checklist will promote
complete and transparent reporting by researchers. The
focus, therefore, is on promoting the quality of reporting of
mapping studies, rather than the quality of their conduct,
although it is possible that the reporting statement will also
indirectly enhance the methodological rigour of the
research [7]. The MAPS statement is primarily targeted at
researchers developing mapping algorithms, the funders of
the research, and peer reviewers and editors involved in the
manuscript review process for mapping studies [5, 6]. In
developing the reporting statement, the term ‘mapping’ is
used to cover all approaches that predict the outputs of
generic preference-based outcome measures using data on
other indicators or measures of health, and encompasses
related forms of nomenclature used by some researchers,
such as ‘cross-walking’ or ‘transfer to utility’ [1, 8].
Similarly, the term ‘algorithm’ is used in its broadest sense
to encompass statistical associations and more complex
series of operations.
2 The Development of the MAPS Statement
The development of the MAPS statement was informed by
recently published guidance for health research reporting
guidelines [5] and broadly modelled other recent reporting
guideline developments [9–14]. A working group com-
prising six health economists (SP, ORA, HD, LL, MO, AG)
and one Delphi methodologist (RF) was formed following
a request from an academic journal to develop a reporting
statement for mapping studies. One of the working group
members (HD) had previously conducted a systematic
review of studies mapping from clinical or health-related
quality-of-life measures onto the EQ-5D [2]. Using the
search terms from this systematic review, as well as other
relevant articles and reports already in our possession, a
broad search for reporting guidelines for mapping studies
was conducted. This confirmed that no previous reporting
guidance had been published. The working group members
therefore developed a preliminary de novo list of 29
reporting items and accompanying explanations. Following
further review by the working group members, this was
subsequently distilled into a list of 25 reporting items and
accompanying explanations.
Members of the working group identified 62 possible
candidates for a Delphi panel from a pool of active
researchers and stakeholders in this field. The candidates
included individuals from academic and consultancy set-
tings with considerable experience in mapping research,
representatives from health technology assessment agen-
cies that routinely appraise evidence informed by mapping
studies, and biomedical journal editors. Health economists
from the MAPS working group were included in the Delphi
panel. A total of 48 of the 62 (77.4 %) individuals agreed
to participate in a Delphi survey aimed at developing a
minimum set of standard reporting requirements for map-
ping studies with an accompanying reporting checklist.
The Delphi panellists were sent a personalised link to a
Web-based survey, which had been piloted by members of
the working group. Non-responders were sent up to two
reminders after 14 and 21 days. The panellists were
anonymous to each other throughout the study and their
identities were known only to one member of the working
group. The panellists were invited to rate the importance of
each of the 25 candidate reporting items identified by the
working group on a 9-point rating scale (1, ‘‘not impor-
tant’’, to 9, ‘‘extremely important’’); describe their confi-
dence in their ratings (‘‘not confident’’, ‘‘somewhat
confident’’ or ‘‘very confident’’); comment on the candidate
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items and their explanations; suggest additional items for
consideration by the panellists in subsequent rounds; and to
provide any other general comments. The candidate
reporting items were ordered within six sections: (1) title
and abstract; (2) introduction; (3) methods; (4) results; (5)
discussion; and (6) other. The panellists also provided
information about their geographical area of work, sex, and
primary and additional work environments. The data were
imported into Stata (version 13; Stata-Corp, College Sta-
tion, TX, USA) for analysis.
A modified version of the Research ANd Development
(RAND)/University of California Los Angeles (UCLA)
appropriateness method was used to analyse the round one
responses [15]. This involved calculating the median score,
the inter-percentile range (IPR) (30th and 70th), and the
inter-percentile range adjusted for symmetry (IPRAS), for
each item (i) being rated. The IPRAS includes a correction
factor for asymmetric ratings, and panel disagreement was
judged to be present in cases if IPRi[ IPRASi [15]. We
modified the RAND/UCLA approach by asking panellists
about ‘importance’ rather than ‘appropriateness’ per se.
Assessment of importance followed the classic RAND/
UCLA definitions, categorised simply as whether the
median rating fell between 1 and 3 (unimportant), 4 and 6
(neither unimportant nor important), or 7 and 9 (important)
[15].
The results of round one of the Delphi survey were
reviewed at a face-to-face meeting of the working group. A
total of 46 of the 48 (95.8 %) individuals who agreed to
participate completed round one of the survey. Of the 25
items, 24 were rated as important, with one item (‘‘Source
of Funding’’) rated as neither unimportant nor important.
There was no evidence of disagreement on ratings of any
items according to the RAND/UCLA method. These find-
ings did not change when the responses of the MAPS
working group were excluded. Based on the qualitative
feedback received in round one, items describing ‘‘Mod-
elling Approaches’’ and ‘‘Repeated Measurements’’ were
merged, as were items describing ‘‘Model Diagnostics’’
and ‘‘Model Plausibility’’. In addition, amendments to the
wording of several recommendations and their explana-
tions were made in the light of qualitative feedback from
the panellists.
Panellists participating in round one were invited to
participate in a second round of the Delphi survey. A
summary of revisions made following round one was
provided. This included a document in which revisions to
each of the recommendations and explanations were dis-
played in the form of track changes. Panellists participating
in round two were provided with group outputs (mean
scores and their standard deviations, median scores and
their IPRs, histograms and RAND/UCLA labels of
importance and agreement level) summarising the round
one results (and disaggregated outputs for the merged
items). They were also able to view their own round one
scores for each item (and disaggregated scores for the
merged items). Panellists participating in round two were
offered the opportunity to revise their rating of the
importance of each of the items and informed that their
rating from round one would otherwise hold. For the
merged items, new ratings were solicited. Panellists par-
ticipating in round two were also offered the opportunity to
provide any further comments on each item or any further
information that might be helpful to the group. Non-re-
sponders to the second round of the Delphi survey were
sent up to two reminders after 14 and 21 days. The ana-
lytical methods for the round two data mirrored those for
the first round.
The results of the second round of the Delphi survey
were reviewed at a face-to-face meeting of the working
group. A total of 39 of the 46 (84.8 %) panellists partici-
pating in round one completed round two of the survey. All
23 items included in the second round were rated as
important with no evidence of disagreement on ratings of
any items according to the RAND/UCLA method. Quali-
tative feedback from the panellists participating in round
two led to minor modifications to wording of a small
number of recommendations and their explanations. This
was fed back to the round two respondents who were given
a final opportunity to comment on the readability of the
final set of recommendations and explanations. Based on
these methods, a final consensus list of 23 reporting items
was developed.
3 The MAPS Statement
The MAPS statement is a 23-item checklist of recom-
mendations (Table 1) that we consider essential for com-
plete and transparent reporting of studies that map onto
generic preference-based outcome measures. The 23
reporting items are presented numerically and categorised
within six sections, namely: (1) title and abstract (two
items); (2) introduction (two items); (3) methods (nine
items); (4) results (six items); (5) discussion (three items);
and (6) other (one item). The reporting of each item does
not necessarily have to follow the order within the MAPS
statement. Rather, what is important is that each recom-
mendation is addressed either in the main body of the
report or its appendices. Several biomedical journals have
endorsed the MAPS statement. These include Applied
Health Economics and Health Policy, Health and Quality
of Life Outcomes, International Journal of Technology
Assessment in Health Care, Journal of Medical Economics,
Medical Decision Making, PharmacoEconomics and
Quality of Life Research. We encourage other journals and
The MAPS Statement
Table 1 Checklist of items to include when reporting a mapping study
Section/topic Item
number
Recommendation Reported on page
number/line number
Title and abstract
Title 1 Identify the report as a study mapping between outcome measures. State the source
measure(s) and generic, preference-based target measure(s) used in the study
_____________
Abstract 2 Provide a structured abstract including, as applicable: objectives; methods,
including data sources and their key characteristics, outcome measures used and
estimation and validation strategies; results, including indicators of model
performance; conclusions; and implications of key findings
_____________
Introduction
Study rationale 3 Describe the rationale for the mapping study in the context of the
broader evidence base
_____________
Study objective 4 Specify the research question with reference to the source and target measures used
and the disease or population context of the study
_____________
Methods
Estimation sample 5 Describe how the estimation sample was identified, why it was selected, the
methods of recruitment and data collection, and its location(s) or setting(s)
_____________
External validation
sample
6 If an external validation sample was used, the rationale for selection, the methods of
recruitment and data collection, and its location(s) or setting(s) should be
described
____________
Source and target
measures
7 Describe the source and target measures and the methods by which they were
applied in the mapping study
_____________
Exploratory data
analysis
8 Describe the methods used to assess the degree of conceptual overlap between the
source and target measures
_____________
Missing data 9 State how much data were missing and how missing data were handled in the
sample(s) used for the analyses
_____________
Modelling approaches 10 Describe and justify the statistical model(s) used to develop the mapping algorithm _____________
Estimation of predicted
scores or utilities
11 Describe how predicted scores or utilities are estimated for each model specification _____________
Validation methods 12 Describe and justify the methods used to validate the mapping algorithm _____________
Measures of model
performance
13 State and justify the measure(s) of model performance that determine the choice of
the preferred model(s) and describe how these measures were estimated and
applied
_____________
Results
Final sample size(s) 14 State the size of the estimation sample and any validation sample(s) used in the
analyses (including both number of individuals and number of observations)
_____________
Descriptive
information
15 Describe the characteristics of individuals in the sample(s) (or refer back to
previous publications giving such information). Provide summary scores for
source and target measures, and summarise results of analyses used to assess
overlap between the source and target measures
_____________
Model selection 16 State which model(s) is(are) preferred and justify why this(these)
model(s) was(were) chosen
_____________
Model coefficients 17 Provide all model coefficients and standard errors for the selected model(s). Provide
clear guidance on how a user can calculate utility scores based on the outputs of
the selected model(s)
_____________
Uncertainty 18 Report information that enables users to estimate standard errors around mean
utility predictions and individual-level variability
_____________
Model performance
and face validity
19 Present results of model performance, such as measures of prediction accuracy and
fit statistics for the selected model(s) in a table or in the text. Provide an
assessment of face validity of the selected model(s)
_____________
Discussion
Comparisons with
previous studies
20 Report details of previously published studies developing mapping algorithms
between the same source and target measures and describe differences between
the algorithms, in terms of model performance, predictions and coefficients, if
applicable
_____________
Study limitations 21 Outline the potential limitations of the mapping algorithm _____________
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research interest groups to endorse the MAPS statement
and authors to adhere to its principles.
4 The MAPS Explanation and Elaboration Paper
In addition to the MAPS reporting statement, we have
produced a supporting Explanation and Elaboration paper
[16] modelled on those developed for other reporting
guidelines [9–14]. The reporting items contained within the
MAPS statement are best understood by referring to the
information contained within this accompanying docu-
ment. The Explanation and Elaboration paper provides
exemplars of good reporting practice identified from the
published literature for each reporting item. In addition, it
provides a detailed explanation to accompany each rec-
ommendation, supported by a rationale and relevant evi-
dence where available. The development of the
Explanation and Elaboration paper was completed fol-
lowing several iterations produced by members of the
working group, after which the examples and explanations
were shared with the Delphi panellists for final revisions to
improve readability and their approval. The Explanation
and Elaboration paper also summarises the characteristics
of the Delphi panellists and provides detailed statistics for
item ratings at each Delphi round.
5 Discussion
Over recent years, there has been a rapid increase in the
publication of studies that use mapping techniques to pre-
dict health utility values. One recent review article identi-
fied 90 studies published up to the year 2013 reporting 121
mapping algorithms between clinical or health-related
quality-of-life measures and the EQ-5D [2]. That review
article excluded mapping algorithms targeted at other
generic preference-based outcome measures that can gen-
erate health utilities, such as the SF-6D [17] and the Health
Utilities Index [18], which have been the target of
numerous other mapping algorithms (e.g. [1, 19–24]).
Moreover, the popularity of the mapping approach for
estimating health utilities is unlikely to wane given the
numerous contexts within health economic evaluation
where primary data collection is challenging. However,
mapping introduces additional uncertainty and collection
of primary data with the preferred utility instrument is
preferable.
The MAPS statement was developed to provide rec-
ommendations, in the form of a checklist of essential items,
which authors should consider when reporting mapping
studies. Guidance for the reporting of mapping studies was
not previously available in the literature. The overall aim of
the MAPS statement is to promote clarity, transparency and
completeness of reporting of mapping studies. It is not
intended to act as a methodological guide, nor as a tool for
assessing the quality of study methodology. Rather, it aims
to avoid misleading conclusions being drawn by readers,
and ultimately policy makers, as a result of sub-optimal
reporting. In keeping with other recent health research
reporting guidelines, we have also produced an accompa-
nying Explanation and Elaboration paper [16] to facilitate a
deeper understanding of the 23 items contained within the
MAPS statement. That paper should hopefully act as a
pedagogical framework for researchers reporting mapping
studies.
The development of the MAPS statement, and its
Explanation and Elaboration document, was framed by
recently published guidance for health research reporting
guidelines [5]. The Delphi panel was composed of a multi-
disciplinary multi-national team of content experts and
journal editors. The panel members included people
experienced in conducting mapping studies; of the 84
researchers who were first authors on papers included in a
recent review of EQ-5D mapping studies [2], 31 (36.9 %)
were included as panellists. We have no evidence to
believe that a larger panel would have altered the final set
of recommendations. The Delphi methodologies that we
applied included analytical approaches only recently
adopted by developers of health reporting guidelines [15].
We are unable to assess whether a strict adherence to the
MAPS checklist will increase the word counts of mapping
Table 1 continued
Section/topic Item
number
Recommendation Reported on page
number/line number
Scope of applications 22 Outline the clinical and research settings in which the mapping
algorithm could be used
_____________
Other
Additional information 23 Describe the source(s) of funding and non-monetary support for the study, and the
role of the funder(s) in its design, conduct and report. Report any conflicts of
interest surrounding the roles of authors and funders
_____________
The MAPS Statement
reports. It is our view that the increasing use of online
appendices by journals should permit comprehensive
reporting even in the context of strict word limits for the
main body of reports.
Evidence for other health research reporting guidelines
suggests that reporting quality improved after the intro-
duction of reporting checklists [25–27], although there is
currently no empirical evidence that adoption of the MAPS
statement will improve the quality of reporting of mapping
research. Future research planned by the MAPS working
group will include a before and after evaluation of the
benefits (and indeed possible adverse effects) of the
introduction of the MAPS statement. It will also be nec-
essary to update the MAPS statement in the future to
address conceptual, methodological and practical advances
in the field. Potential methodological advances that might
be reflected in an update might include shifts toward more
complex model specifications, better methods for dealing
with uncertainty and guidance on appropriate use of mea-
sures of prediction accuracy, such as mean absolute error
and mean square error. The MAPS working group plans to
assess the need for an update of the reporting checklist in
5 years’ time.
6 Conclusion
This paper summarises a new reporting statement devel-
oped for studies that map onto generic preference-based
outcome measures. We encourage health economics and
quality-of-life journals to endorse the MAPS statement,
promote its use in peer review, and update their editorial
requirements and ‘Instructions to Authors’ accordingly.
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